WebJan 17, 2024 · In this episode, Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology University of Oxford and academic lead for the work package in EHDEN focusing on the generation of real world evidence, talks about COVID-19, and how new, open science ways of working such as study-a-thons are influencing medical research. WebI am an academic clinician and a professor in pharmaco-epidemiology at the University of Oxford. I have experience in the curation, analysis, and interpretation of 'real world data' (electronic medical records, health claims, registries, and other routinely collected data sources) to inform the use, risks, and benefits of medicines, devices, and vaccines in …
Dani Prieto-Alhambra on LinkedIn: Contextualising adverse …
WebApr 30, 2024 · A team from NDORMS has been researching the safety profile of hydroxychloroquine, either alone or in combination with azithromycin, after the drugs were suggested to be an effective treatment for COVID-19. The NDORMS team, including Prof Dani Prieto-Alhambra and Jenny Lane, joined with over 300 international researchers … WebFeb 27, 2024 · • Dani Prieto-Alhambra recently shared an opening for a Database Programmer to join the Health Data Sciences research group at the University of Oxford. According to the posting, you will develop new database applications for big clinical data to meet project requirements and deadlines, provide software feedback and carry out … johnny glitter force
领英上的Álvaro Inglés-Prieto: Impedance-based phenotypic …
WebDani Prieto-Alhambra. MD MSc(Oxf) PhD. Professor of Pharmaco- and Device Epidemiology. Section Head, Health Data Sciences, Botnar Research Centre NIHR … WebApr 5, 2024 · This is the largest #covid19 study I know of, including almost 24m people with covid and over 945m 'general population' participants from 26 data sources… WebAU - Prieto Alhambra, D. (Dani) N1 - Funding Information: TD-S declares no competing interests. DP-A's research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma, … johnny glock timney alpha